To evaluate the effectiveness and safety of obinutuzumab compared to tacrolimus in patients with primary membranous nephropathy

Agree to participate in one of two treatment groups, attend scheduled study visits and have blood drawn for samples. will have visits approximately every 2 to 14 weeks during the first two years of the study, every 12-16 weeks in the third and fourth years of the study, and then every 26 weeks until you finish the study. Visits will usually last 1-3 hours, but visits that require an obinutuzumab infusion may last 6 hours. Your total time in the study will be a minimum of about 4 years, but could be up to about 9 years, depending on how the treatment affects your disease.

$100.00 per visit